Targeting TGF-ß in the Central Nervous System: Assessment of Cynomolgus Monkey—Toxicity and Pharmacokinetics for an LNA-Antisense Oligonucleotide release_725xgwgg6bf2xebypqmlsf7oci

by Sebastian Thomas Peters, Eva Wirkert, Sabrina Kuespert, Rosmarie Heydn, Sven Korte, Lars Mecklenburg, Ludwig Aigner, Siw Johannesen, Tim-Henrik Bruun, Ulrich Bogdahn

Published by Universität Regensburg.



Increasingly antisense oligonucleotides (ASOs) are developed for potential treatment of CNS disorders, and due to the inability to cross the blood brain barrier, they require direct administration into the cerebrospinal fluid (CSF). In this regard, intrathecal ( administration in cynomolgus monkeys (Macaca fascicularis) is a well-established approach for preclinical safety studies. Here, we present an innovative preclinical approach that is intended to support rapid entry into clinical development with ASOs targeting the CNS. The preclinical approach comprises one non-GLP study in 26 non-human primates, followed by a pivotal GLP repeated dose toxicity study in the same species. No pivotal rodent studies were conducted, and regulatory guidance to initiate this study was met by in vitro work. The non-GLP study consists of three separate phases: Phase A determines toxicity after administrations with five escalating dose levels in a single male and female animal, respectively. Dosing is conducted on days 1, 8, 15, 22, and 29 and the experiment is terminated 36 days after start of the study. The second phase (Phase B) investigates pharmacokinetics over a 2- or 4-week period at two dose levels following single administrations in eight (8) animals (4 females, 4 males). Finally, a third phase (Phase C) investigates toxicity and pharmacokinetics after repeated (9×) dosing over a 13-week period at two dose levels in sixteen (8 females, 8 males) animals. In each phase, clinical observations and physical/neurological parameters are investigated directly pre-dose, 4 h and 24 h post-dose, respectively. In all phases, CSF and blood samples are taken pre-dose and after each dosing, for determination of test article concentration, biomarkers of tolerability and biomarkers of pharmacology. In all phases, tissue samples from the liver, kidney, spinal cord, and brain are collected for determination of NVP-13 tissue concentrations. The above concept has successfully supported first-in-human clinical trials. The entire non [...]
In text/plain format

Archived Files and Locations

application/pdf  3.1 MB
file_cyaq4hjopvfxxagvxy24fbfgaa (publisher) (webarchive)
Read Archived PDF
Preserved and Accessible
Type  article-journal
Stage   published
Year   2022
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: e6fd7d19-31f8-45cd-8d57-e0c97e02fc15